Growing synergy of nanodiamonds in neurodegenerative interventions.


Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
02 2019
Historique:
received: 31 08 2018
revised: 30 09 2018
accepted: 22 10 2018
pubmed: 9 11 2018
medline: 1 8 2019
entrez: 9 11 2018
Statut: ppublish

Résumé

Neurodegenerative diseases are complex in both their nature and prognosis. The difficulties associated with penetrating the blood-brain barrier (BBB), achieving site-specific targeting to the brain, and identifying the genetic etiologies responsible make treating neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and stroke, challenging. The aim to treat disease at the molecular level has galvanized nanotechnology research. Among the forms of nanoparticles (NPs) explored thus far, nanodiamonds (NDs) have shown great potential. Their unique physicochemical properties, such as a nanometer size range, stable and inert core, tunable surface, intrinsic fluorescence without photobleaching, negligible toxicity, and the ability to form complexes with drugs, highlight their theranostic potential. The ability of NDs to penetrate the BBB and target specific affected areas of the brain could take research one step closer to understanding the underlying disease etiology and unlocking more efficient methods of delivering neuromedicine to specific areas of the brain. Here, we explore interactions between NDs and the neuronal circuitry with a focus on the therapeutic potential of NDs as treatments for neurodegenerative diseases.

Identifiants

pubmed: 30408527
pii: S1359-6446(18)30363-5
doi: 10.1016/j.drudis.2018.10.012
pii:
doi:

Substances chimiques

Nanodiamonds 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

584-594

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Jackson Saraf (J)

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, Gandhinagar 382355, Gujarat, India.

Kiran Kalia (K)

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, Gandhinagar 382355, Gujarat, India.

Pallab Bhattacharya (P)

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, Gandhinagar 382355, Gujarat, India. Electronic address: pallab.bhattacharya@niperahm.ac.in.

Rakesh Kumar Tekade (RK)

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, Gandhinagar 382355, Gujarat, India. Electronic address: rakeshtekade@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH